SD BioScience Acquires 27.87% Stake in Immunobiotech for 5.3 Billion KRW
[Asia Economy Reporter Jang Hyowon] SD Bioscience announced on the 14th that it will acquire 1,668,738 shares (27.87%) of Immunobiotech for 5.3 billion KRW.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
The acquisition method involves cash payment and convertible bond sales. The purpose of the acquisition is to promote new business. Immunobiotech is a company engaged in the manufacturing and sales of probiotic raw materials and finished products.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
